Sanofi and immunext reach a US $500 million cooperation in the field of autoimmune diseases

Source: Sina medical news on January 9, 2017, immunext and Sanofi reached a cooperation agreement, mainly focusing on the development and research of innovative protein drugs in the field of autoimmune disorders According to the agreement, immunext's milestone payment in the cooperation will reach US $500 million, with double-digit sales commission revenue "Sanofi is committed to the expansion of product pipeline in multiple sclerosis and immune diseases," said Dr Frank Nestle, global leader of immune and inflammatory diseases of Sanofi and CSO in North America In the field of multiple sclerosis, we have a strong R & D foundation In terms of immune diseases, we plan to launch new drugs for the treatment of specific dermatitis and rheumatoid arthritis this year We are very excited to work with Dr Noelle and his team at immunext " Inx-201, a monoclonal antibody candidate drug targeting CD40L, is in the pre clinical research and development stage, and has good therapeutic potential for a variety of autoimmune diseases such as lupus erythematosus and multiple sclerosis In the future, the two companies will work together to promote the clinical development of the drug Dr Randolph Noelle, founder and professor of Microbiology and immunology of immunenext company, and professor of Microbiology and immunology of Geiser Medical College, Dartmouth, also said: "immunomodulator CD40L is a key factor in the development of a series of autoimmune diseases The therapeutic effect of antibody blocking CD40L has been verified in the pre clinical autoimmune disease model In the field of autoimmune diseases, anti CD40L therapy provides an excellent treatment for delaying disease progression and maintaining long-term disease remission " One month before the announcement, immunext and Roche have just reached a cooperation agreement on Vista (T cell activated immunoglobulin V-domain inhibitor) signal pathway agonist immunotherapy The partnership will bring immunext $400 million in mileage plus double-digit sales commission.